Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 18/20 | 0.38 |
| ▸ | NOS1 | P29475 | 15/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559827 | 0.84 | NOS2 (0.44) | NOS2NOS1PDE5APTGS1TBXAS1 | |
| SCHEMBL3566770 | 0.82 | ADRB2 (0.32) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL3559740 | 0.78 | NOS2 (0.46) | NOS2NOS1 | |
| SCHEMBL3560293 | 0.76 | NOS2 (0.48) | NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL3563512 | 0.76 | NOS2 (0.48) | NOS2NOS1 | |
| SCHEMBL3556543 | 0.75 | NOS2 (0.51) | NOS2NOS1 | |
| SCHEMBL3567376 | 0.74 | NOS2 (0.51) | NOS2NOS1 | |
| SCHEMBL3562883 | 0.73 | NOS2 (0.39) | NOS2NOS1PDE5ANPC1TSHR | |
| SCHEMBL3571843 | 0.72 | NOS2 (0.51) | NOS2NOS1 | |
| SCHEMBL3570858 | 0.71 | NOS2 (0.55) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825256-B2 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | KALYPSYS, INC. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116515-A1 | Inducible nitric oxide synthase dimerization inhibitors | NOS3, NOS2, NOS1 | NOS2 2/4885NOS1 3/4885PDE5A 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.